CLAIMS

1. Use of a classical complement pathway inhibitor in the manufacture of a medicament for inhibiting an immune response to transfused platelets in a subject, wherein the subject is to be transfused with said platelets.

2. Use of a classical complement pathway inhibitor in the manufacture of a medicament for inhibiting refractoriness to platelets in an alloimmunized subject, wherein said platelets have been treated with said classical complement pathway inhibitor; and the treated platelets are to be transfused to the subject.

3. Use of a classical complement pathway inhibitor in the manufacture of a medicament for preventing platelet refractoriness in a subject receiving platelets from an antigenically mismatched donor, wherein the classical complement pathway inhibitor is to be administered to the subject before the platelets are to be transfused to the subject.

4. Use of a classical complement pathway inhibitor in the manufacture of a medicament for preventing platelet refractoriness in a subject receiving platelets from an antigenically mismatched donor, wherein the platelets are treated with said classical complement pathway inhibitor and wherein said treated platelets are to be transfused to the subject.5. The use of any one of claims 1 to 4, wherein the use is effective to increase survival of the transfused platelets in the subject.

6. The use of any one of claims 1 to 5, wherein the use is effective to reduce complement-mediated attack of the transfused platelets in the subject.

7. The use of any one of claims 1 to 6, wherein the use is effective to increase survival of the transfused platelets in the subject.

8. The use of any one of claims 1 to 7, wherein the subject is human.

9. The use of any one of claims 1 to 7, wherein the complement mediated inhibitor is a PIC1 peptide.

10. The use of claim 9, wherein the PIC1 peptide comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOS: 1-45.

11. The use of claim 10, wherein the PIC1 peptide comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOS: 3, 4, 5, 6, 9, 10, 19, and 29.

12. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 3.

13. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 4.

14. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 5.

15. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 6.

16. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 9.

17. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 10.

18. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 19.

19. The use of claim 11, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 29.

20. A blood product for use in transfusion into a recipient, wherein the blood product comprises platelets and a classical complement pathway inhibitor.

21. The blood product of claim 20, wherein the complement mediated inhibitor is a PIC1 peptide.

22. The blood product of claim 21, wherein the PIC1 peptide comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOS: 3, 4, 5, 6, 9, 10, 19, and 29.

23. The blood product of claim 22, wherein the PIC1 peptide comprises the amino acid sequence of any one of SEQ ID NOS: 3, 4, 5, 6, 9, 10, 19, and 29.

24. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 3.

25. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 4.

26. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 5.

27. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 6.

28. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 9.

29. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 10.

30. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 19.

31. The blood product of claim 23, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 29.

32. Use of a classical complement pathway inhibitor in the manufacture of a medicament for treating delayed hemolytic transfusion reaction (DHTR) in a subject wherein a therapeutically effective amount of the classical complement pathway inhibitor is to be administered to the subject.

33. The use of claim 32, wherein the classical complement pathway inhibitor is to be administered parenterally.

34. The use of claim 32 or claim 33, wherein the subject is human.

35. The use of any one of claims 32 to 34, wherein the complement mediated inhibitor is a PIC1 peptide.

36. The use of claim 35, wherein the PIC1 peptide comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOS: 3, 4, 5, 6, 9, 10, 19, and 29.

37. The use of claim 36, wherein the PIC1 peptide comprises the amino acid sequence of any one of SEQ ID NOS: 3, 4, 5, 6, 9, 10, 19, and 29.

38. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 3.

39. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 4.

40. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 5.

41. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 6.

42. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 9.

43. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 10.

44. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 19.

45. The use of claim 37, wherein the PIC1 peptide comprises the amino acid sequence of SEQ ID NO: 29.